Revance Therapeutics, Stock Number Of Shares Shorted
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
Revance Therapeutics, fundamentals help investors to digest information that contributes to Revance Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Revance Stock. The fundamental analysis module provides a way to measure Revance Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Revance Therapeutics, stock.
Revance |
Revance Therapeutics, Company Number Of Shares Shorted Analysis
Revance Therapeutics,'s Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Revance Therapeutics, Number Of Shares Shorted | 4.51 M |
Most of Revance Therapeutics,'s fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revance Therapeutics, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
CompetitionBased on the recorded statements, Revance Therapeutics, has 4.51 M of outstending shares currently sold short by investors. This is 41.03% higher than that of the Pharmaceuticals sector and 11.48% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 4.11% higher than that of the company.
Revance Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revance Therapeutics,'s direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revance Therapeutics, could also be used in its relative valuation, which is a method of valuing Revance Therapeutics, by comparing valuation metrics of similar companies.Revance Therapeutics, is currently under evaluation in number of shares shorted category among its peers.
Revance Fundamentals
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.54) % | |||
| Current Valuation | 680.39 M | |||
| Shares Outstanding | 104.39 M | |||
| Shares Owned By Insiders | 8.55 % | |||
| Shares Owned By Institutions | 87.45 % | |||
| Number Of Shares Shorted | 4.51 M | |||
| Price To Earning | (7.60) X | |||
| Price To Book | 12.30 X | |||
| Price To Sales | 1.48 X | |||
| Revenue | 234.04 M | |||
| Gross Profit | 103.69 M | |||
| EBITDA | (290.64 M) | |||
| Net Income | (323.99 M) | |||
| Cash And Equivalents | 233.82 M | |||
| Cash Per Share | 3.20 X | |||
| Total Debt | 478.43 M | |||
| Debt To Equity | 2.94 % | |||
| Current Ratio | 3.38 X | |||
| Book Value Per Share | (1.55) X | |||
| Cash Flow From Operations | (216.57 M) | |||
| Short Ratio | 1.70 X | |||
| Earnings Per Share | (3.34) X | |||
| Price To Earnings To Growth | (0.64) X | |||
| Target Price | 9.47 | |||
| Number Of Employees | 597 | |||
| Beta | 0.95 | |||
| Market Capitalization | 381.02 M | |||
| Total Asset | 478.45 M | |||
| Retained Earnings | (2.08 B) | |||
| Working Capital | 249.64 M | |||
| Current Asset | 208.68 M | |||
| Current Liabilities | 17.52 M | |||
| Net Asset | 478.45 M |
About Revance Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revance Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revance Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revance Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |